Brief: Antengene Corp Announces Approval Of Phase Ii Study Of Selinexor By Nmpa
23/08/2021 16:02
Aug 23 (Reuters) - Antengene Corporation Ltd 6996.HK :
* APPROVAL OF PHASE II STUDY OF SELINEXOR BY NMPA FOR
TREATMENT OF
MYELOFIBROSIS IN CHINA
Further company coverage: 6996.HK
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106